Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $285,710 | $363,468 | $312,690 | $252,002 |
| % Growth | -21.4% | 16.2% | 24.1% | – |
| Cost of Goods Sold | $984 | $3,100 | $5,322 | $4,212 |
| Gross Profit | $284,726 | $360,368 | $307,368 | $247,790 |
| % Margin | 99.7% | 99.1% | 98.3% | 98.3% |
| R&D Expenses | $176,639 | $185,272 | $191,485 | $242,799 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $176,303 | $230,855 | $332,493 | $317,418 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2,155 | $4,414 | $0 |
| Operating Expenses | $352,942 | $416,127 | $523,978 | $560,217 |
| Operating Income | -$68,216 | -$55,759 | -$216,610 | -$312,427 |
| % Margin | -23.9% | -15.3% | -69.3% | -124% |
| Other Income/Exp. Net | -$106,642 | -$35,667 | -$43,640 | -$32,254 |
| Pre-Tax Income | -$174,858 | -$91,426 | -$274,880 | -$344,681 |
| Tax Expense | -$290,032 | $53,596 | $49,350 | $46,371 |
| Net Income | $115,174 | -$145,022 | -$324,230 | -$391,052 |
| % Margin | 40.3% | -39.9% | -103.7% | -155.2% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 |
| % Growth | 174.9% | 53.7% | 20.4% | – |
| EPS Diluted | 3.4 | -4.55 | -9.83 | -12.35 |
| Weighted Avg Shares Out | 33,822 | 31,858 | 32,970 | 31,654 |
| Weighted Avg Shares Out Dil | 33,837 | 31,894 | 32,970 | 31,654 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15,511 | $47,768 | $39,802 | $33,352 |
| Interest Expense | $21,385 | $54,419 | $48,054 | $41,144 |
| Depreciation & Amortization | $6,521 | $2,155 | $4,414 | $8,890 |
| EBITDA | -$61,695 | -$34,852 | -$212,196 | -$294,647 |
| % Margin | -21.6% | -9.6% | -67.9% | -116.9% |